High-titer rAAV production in bioreactors using ELEVECTA™ stable producer cell lines

This application note presents the development and optimization of a novel AAV production platform, ELEVECTA™, designed to enhance recombinant adeno-associated virus (rAAV) yield and quality, addressing key challenges in viral gene therapy. This platform demonstrates a robust approach for scalable AAV manufacturing by utilizing mammalian suspension cells with a stable integration of all required AAV production components—including adenovirus helper functions, AAV replicase, AAV capsid, and a gene of interest (GOI). The research highlights an upstream process optimization of an AAV8-GFP proof-of-concept (PoC) producer single cell clone (SCC), comparing batch and perfusion modes to identify optimal conditions for enhanced productivity and efficiency in AAV vector production.